Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of omega-3 supplementation on psychological symptoms in men with prostate cancer: Secondary analysis of a double-blind placebo-controlled randomized trial.
Savard J, Moussa H, Pelletier JF, Julien P, Lacombe L, Tiguert R, Caumartin Y, Dujardin T, Toren P, Pouliot F, Lodde M, Fradet Y, Robitaille K, Fradet V. Savard J, et al. Among authors: pouliot f. Cancer Med. 2023 Oct;12(19):20163-20176. doi: 10.1002/cam4.6598. Epub 2023 Oct 3. Cancer Med. 2023. PMID: 37787025 Free PMC article. Clinical Trial.
Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic-mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer.
Gonthier K, Weidmann C, Berthiaume L, Jobin C, Lacouture A, Lafront C, Harvey M, Neveu B, Loehr J, Bergeron A, Fradet Y, Lacombe L, Riopel J, Latulippe É, Atallah C, Shum M, Lambert JP, Pouliot F, Pelletier M, Audet-Walsh É. Gonthier K, et al. Among authors: pouliot f. Mol Oncol. 2023 Oct;17(10):2109-2125. doi: 10.1002/1878-0261.13441. Epub 2023 Jul 19. Mol Oncol. 2023. PMID: 37086156 Free PMC article.
The estrogen signaling pathway reprograms prostate cancer cell metabolism and supports proliferation and disease progression.
Lafront C, Germain L, Campolina-Silva GH, Weidmann C, Berthiaume L, Hovington H, Brisson H, Jobin C, Frégeau-Proulx L, Cotau R, Gonthier K, Lacouture A, Caron P, Ménard C, Atallah C, Riopel J, Latulippe É, Bergeron A, Toren P, Guillemette C, Pelletier M, Fradet Y, Belleannée C, Pouliot F, Lacombe L, Lévesque É, Audet-Walsh É. Lafront C, et al. Among authors: pouliot f. J Clin Invest. 2024 Apr 16:e170809. doi: 10.1172/JCI170809. Online ahead of print. J Clin Invest. 2024. PMID: 38625747 Free article.
Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study.
Morris MJ, Rowe SP, Gorin MA, Saperstein L, Pouliot F, Josephson D, Wong JYC, Pantel AR, Cho SY, Gage KL, Piert M, Iagaru A, Pollard JH, Wong V, Jensen J, Lin T, Stambler N, Carroll PR, Siegel BA; CONDOR Study Group. Morris MJ, et al. Among authors: pouliot f. Clin Cancer Res. 2021 Jul 1;27(13):3674-3682. doi: 10.1158/1078-0432.CCR-20-4573. Epub 2021 Feb 23. Clin Cancer Res. 2021. PMID: 33622706 Free PMC article. Clinical Trial.
Evaluating the impact of early identification of asymptomatic brain metastases in metastatic renal cell carcinoma.
Parmar A, Ghosh S, Sahgal A, Lalani AA, Hansen AR, Reaume MN, Wood L, Basappa NS, Heng DYC, Graham J, Kollmannsberger C, Soulières D, Breau RH, Tanguay S, Kapoor A, Pouliot F, Bjarnason GA. Parmar A, et al. Among authors: pouliot f. Cancer Rep (Hoboken). 2023 Mar;6(3):e1763. doi: 10.1002/cnr2.1763. Epub 2022 Dec 14. Cancer Rep (Hoboken). 2023. PMID: 36517084 Free PMC article.
2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer Full-text.
So AI, Chi K, Danielson B, Fleshner NE, Kinnaird A, Kapoor A, Niazi T, Pouliot F, Rendon RA, Shayegan B, Sridhar SS, Vigneault E, Saad F. So AI, et al. Among authors: pouliot f. Can Urol Assoc J. 2022 Dec;16(12):E581-E589. doi: 10.5489/cuaj.8148. Can Urol Assoc J. 2022. PMID: 36656694 Free PMC article. No abstract available.
2023 UPDATE - Canadian Urological Association guideline: Management of cystic renal lesions Prior to original publication (March 2017), this guideline underwent review by the CUA Guidelines Committee, CUA members at large, and the CUA Executive Board. The 2023 updates were app roved by the CUA Guidelines Committee and CUA Executive Board.
Richard PO, Violette PD, Bhindi B, Breau RH, Gratton M, Jewett MAS, Kapoor A, Pouliot F, Leveridge M, So AI, Whelan TF, Rendon RA, Tanguay S, Finelli A. Richard PO, et al. Among authors: pouliot f. Can Urol Assoc J. 2023 Jun;17(6):162-174. doi: 10.5489/cuaj.8389. Can Urol Assoc J. 2023. PMID: 37310905 Free PMC article. No abstract available.
169 results